JucaBio, LLC was established to build biotech companies around promising, novel therapeutics in areas of high unmet need.

CinCor, founded in 2018, is a clinical-stage biopharmaceutical company with a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases. It’s lead asset, baxdrostat, a first -in-class aldosterone synthase inhibitor, is in clinical development for the treatment of hypertension and primary aldosteronism. CinCor Pharma was acquired by AstraZeneca in Q1 2023 for $1.8 billion in total consideration.

CinRx Pharma is a biopharmaceutical company developing novel therapeutics that address substantial unmet medical needs across diverse disease indications. CinRx does this through partnering (JV, co-developing, direct venture investment) to design and implement critical development activities that will enhance the value of the underlying asset. CinRx’s unique structure and depth of experience allows the Company to act as an operational partner, as well as a capital syndication partner.

Seed-stage venture capital company investing in Information Technology, Healthcare, and Healthcare IT. Major exits/IPOs include AssureX Health (acquired by Myriad Genetics), Akebia Therapeutics (AKBA), Aerpio Therapeutics (ARPO), Blue Ash Therapeutics (acquired by Forest Laboratories), Ilesfay (acquired by Autodesk), and Workflex (acquired by Nice Technologies).